Majid Zeidi
Overview
Explore the profile of Majid Zeidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Werth V, Hejazi E, Pena S, Haber J, Zeidi M, Reddy N, et al.
J Invest Dermatol
. 2022 May;
142(10):2651-2659.e1.
PMID: 35490744
Background: Treatment options are limited for skin disease in dermatomyositis. Lenabasum is a cannabinoid receptor type 2 agonist that triggers the resolution of inflammation. Objective: The objective of this study...
2.
Maddukuri S, Patel J, Diaz D, Chen K, Wysocka M, Bax C, et al.
Arthritis Res Ther
. 2022 Mar;
24(1):69.
PMID: 35277198
No abstract available.
3.
Zeidi M, Chen K, Patel J, Desai K, Kim H, Chakka S, et al.
Lupus
. 2022 Mar;
31(4):472-481.
PMID: 35258358
Background: Antimalarials are first-line systemic therapy for cutaneous lupus erythematosus (CLE). While some patients unresponsive to hydroxychloroquine (HCQ) alone benefit from the addition of quinacrine (QC), a subset of patients...
4.
Maddukuri S, Patel J, Diaz D, Chen K, Wysocka M, Bax C, et al.
Arthritis Res Ther
. 2022 Jan;
24(1):12.
PMID: 34983619
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic...
5.
Chen K, Patel J, Zeidi M, Wysocka M, Bashir M, Patel B, et al.
J Invest Dermatol
. 2021 Mar;
141(8):1906-1914.e2.
PMID: 33675790
Dermatomyositis pathogenesis remains incompletely understood; however, recent work suggests a predominant IFN-1 response. We explored dermatomyositis pathogenesis by quantifying the inflammatory cells in the skin, comparing myeloid with plasmacytoid dendritic...
6.
Zeidi M, Chen K, Patel B, Ravishankar A, Lim R, Werth V
J Cutan Pathol
. 2020 Sep;
48(3):364-373.
PMID: 32954523
Background: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of DM patients has skin biopsies showing spongiotic dermatitis (SD), a histopathology more commonly seen...
7.
Bax C, Chakka S, Concha J, Zeidi M, Werth V
J Am Acad Dermatol
. 2020 Jun;
84(4):1051-1058.
PMID: 32553683
The use of herbal supplements that promise to improve immune health has gained popularity among dermatology patients. However, there is little to no evidence that herbal supplements improve dermatologic conditions....
8.
Chen K, Zeidi M, Werth V
Curr Rheumatol Rep
. 2019 Sep;
21(10):53.
PMID: 31473845
Purpose Of The Review: Dermatomyositis (DM) is an uncommon autoimmune disease that primarily affects the skin, muscle, and/or lungs, and remains a therapeutic challenge. We discuss recent studies evaluating efficacy...
9.
Zeidi M, Kim H, Werth V
J Invest Dermatol
. 2018 Sep;
139(2):324-332.
PMID: 30227141
Although antimalarials are the primary treatment for cutaneous lupus erythematosus, not all patients are equally responsive. We investigated whether different inflammatory cell population and cytokine profiles in lesional cutaneous lupus...
10.
Zeidi M, Chansky P, Werth V
J Am Acad Dermatol
. 2018 Aug;
80(3):801-804.
PMID: 30165168
No abstract available.